Entecavir

Entecavir

File:Entecavir structure.svg
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Entecavir
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	J05AF10 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	13%
Elimination half-life	128–149 hours
Excretion	Renal 62–73%
Identifiers
IUPAC name 2-amino-9-[4-hydroxy-3-(hydroxymethyl)- 2-methylidene-cyclopentyl]-3H-purin-6-one
CAS Number	142217-69-4
PubChem CID	153941
DrugBank	APRD00948
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H15N5O3
Molar mass	277.279 g/mol

Entecavir (INN) (Template:PronEng) is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).

Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.

External links

• Baraclude U.S. website